MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LabCorp and Mount Sinai to Create AI-Fueled Digital Pathology Center

The collaboration calls for the use of the Philips IntelliSite Pathology Solution to expand the digital pathology capabilities at Mount Sinai Health System.

Some of the biggest names in healthcare are coming together to form a digital and artificial intelligence-enabled pathology center of excellence. LabCorp and Mount Sinai Health System are the primary architects for the center, with a huge assist from Philips.

The Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence will be housed within the New York-based health system’s department of Pathology, Molecular and Cell-Based Medicine and will use the Philips IntelliSite Pathology Solution to expand digital pathology capabilities for primary diagnosis and consultations.

The collaboration will have Burlington, NC-based LabCorp, which has implemented the Philips IntelliSite Pathology Solution in four of its laboratories, use its experience and expertise to lead the integration of digital pathology into clinical practice across Mount Sinai’s hospitals. Initially, digital pathology will be used for interpretations of genitourinary malignancies, mainly prostate tumors, as well as cancers of the head and neck.

The next planned stage of implementation is for Mount Sinai pathologists to use the digital pathology solution to provide consultations for cases interpreted by LabCorp’s Dianon Pathology specialty laboratory. This will give physicians and patients from across the U.S. access to the leading expertise of Mount Sinai specialists.

“Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases," said Carlos Cordon-Cardo, MD, PhD, chairman of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System and professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. "This, in addition to our new predictive AI-based tests, introduces the potential for optimization of treatment efficacy, and provides the opportunity for improved clinical outcomes."

Filed Under
500 characters remaining